Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mesenchymal stem cells (University College London)
- Development stage
- Unknown
- Lead developer
- University College London
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intratendinous Injection
01
Overview
This autologous bone marrow-derived mesenchymal stem cell (BMMSC) therapy is an Advanced Therapy Medicinal Product (ATMP) developed by University College London for the treatment of chronic midportion Achilles tendinopathy. The therapy involves the extraction of a patient's own bone marrow, followed by the culture-expansion of mesenchymal stem cells, which are then injected directly into the damaged Achilles tendon. The mechanism of action relies on the stem cells' capacity for self-renewal and differentiation into tenocytes, as well as their ability to secrete paracrine factors that modulate inflammation and promote tissue repair. A Phase IIa proof-of-concept trial (ASCAT) demonstrated the safety and potential efficacy of this approach in improving pain and functional scores in patients with chronic tendinopathy.
- Other names
- autologous mesenchymal stem cellsBMMSCautologous cultured mesenchymal stem cellsautologous bone marrow-derived mesenchymal stem cells
Beyond the preview
Go deeper on autologous bone marrow-derived mesenchymal stem cells (University College London).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stem cells (University College London).